Review Article

Vitamin K Dependent Proteins and the Role of Vitamin K2 in the Modulation of Vascular Calcification: A Review

Margueritta S. El Asmar, Joseph J. Naoum and Elias J. Arbid

Received: 8 Feb 2014 / Accepted: 9 Apr 2014 © OMSB, 2014

Abstract

Vascular calcification, a cause of cardiovascular morbidity and mortality, is an actively regulated process involving vitamin K dependent proteins (VKDPs) among others. Vitamin K is an essential micronutrient, present in plants and animal fermented products that plays an important role as a cofactor for the post-translational γ-carboxylation of glutamic acid residues in a number of proteins. These VKDPs require carboxylation to become biologically active, and they have been identified as having an active role in vascular cell migration, angiogenesis and vascular calcification. This paper will review the process of vascular calcification and delineate the role that vitamin K2 plays in the modulation of that process, through the activation of VKDPs. One such VKDP is Matrix Gla Protein (MGP), which when activated inhibits osteogenic factors, thereby inhibiting vascular and soft tissue calcification.

Keywords: Vitamin K; Vitamin K2; Menaquinone; Vascular Calcification; Matrix glutamate-Protein (MGP); Warfarin; Vitamin K antagonists.

Introduction

Vascular Calcification

Evidence that the process of vascular calcification is a regulated one and is present even in the early stages of disease has surfaced, drawing the attention of scientists and clinicians to study its regulation, in an effort to find possible inhibitors or substances that induce its regression. Vascular calcification is characterized by the deposition of calcium phosphate complexes mostly in the form of hydroxyapatite. It can present as medial calcification or intimal calcification. Medial calcification, or Monckeberg’s medial sclerosis, is prevalent among diabetic patients and patients with renal or hyperparathyroid disease.11 Intimal calcification occurs on the surface of atherosclerotic plaques,1 while medial calcification is normally associated with the elastic lamina.4

Several factors including hypertension, inflammation, oxidized low density lipoproteins (oxLDL), stress, hypercalcemia, hyperphosphatemia and a high calcium-phosphorous ion product (Ca × P) can influence and transform vascular smooth muscle cells (VSMC) into osteocyte-like cellular elements through the transcription of osteochondrogenic morphogens.5,6 Notably, these inducing factors are increased among patient populations with a prevalent incidence of vascular calcification, namely patients with diabetes, renal dysfunction and atherosclerosis. The role that secreted osteochondrogenic factors (the polypeptides also responsible for bone morphogenesis during skeletal development and fracture repair) play in the pathophysiology of vascular calcification has become better appreciated.7 On the molecular level, one of the factors that both initiates and contributes to the calcification process is a reduction in the expression of vitamin K dependent calcification-inhibiting proteins such as matrix gla-protein (MGP).8 One such mechanism by which MGP plays its role is through the inhibition of such osteogenic factors. Therefore, the same mechanisms that govern skeletal calcification also cause vascular calcification, in the absence or inactivation of soft tissue calcification inhibitors such as MGP9

Vitamin K and its Dependent Proteins

Vitamin K is a lipid-soluble vitamin that was first identified by Henrik Dam in 1929 for its anti-hemorrhagic activities.10-13 It was later coined with the letter K for the Danish word Koagulation. It consists of a group of vitamins that may be further classified as vitamin K1 (VK1) or phylloquinone; vitamin K2 (VK2) ormenaquinone; and vitamin K3 (VK3) or menadione.14 Vitamin K compounds share the same 2-methyl-1, 4-naphthoquinone backbone, yet differ by the substituent on the third carbon of the naphthoquinone ring.15 VK’s substituent is a phytol chain on the 3’ position, is mainly found in plants and is involved with photosynthesis.14,16 VK2 is formed mostly by bacteria. Humans may obtain VK2 from fermented dietary sources, such as curd cheese and natto, a Japanese food, or convert high doses of VK1 into VK2 in their bodies.17,18 Vitamin K1 is a synthetic vitamin K with no organic moiety on the 3’ position.14 Vitamin K is mainly found in food in the unreduced quinine (K) form that is in turn reduced into hydroquinone (KH) in the body. Of importance, Vitamin K is present in significantly lower quantities as compared to the amount of γ-carboxylation that takes place, which suggests that this vitamin is recycled in the body through the vitamin K cycle, presented in Fig. 2.

Margueritta S. El Asmar
School of Medicine, American University of Beirut, Beirut, Lebanon.

Joseph J. Naoum, Elias J. Arbid
Department of Surgery, Section of Vascular and Endovascular Surgery, University Medical Center Rizk Hospital, Lebanese American University, P.O. Box 11-3288, Beirut, Lebanon.
E-mail: elias.arbid@umcrh.com
Matrix Gla protein (MGP)

Matrix Gla protein (MGP), an extracellular protein, is a VKD protein that plays a major role in the process of vascular calcification. Gla-containing proteins were detected in human and porcine calcified aortic valves while none were found in normal and stenotic tissues. Subsequently, MGP gene knock-out mice were shown to develop soft-tissue calcification, similar to that observed in humans suffering from Keutel syndrome, a disease resulting in defective MGP synthesis. More recently, MGP has been shown to have an inhibitory role on the process of vascular calcification.

The relationship between MGP and Vitamin K lies in the fact that inactive MGP requires vitamin K to carboxylate it for its activation. Since MGP is a peripheral protein, Vitamin K, the most prevalent form of vitamin K in non-hepatic tissue – is the vitamin mostly available to carboxylate MGP. As calcification develops, MGP is up-regulated in VSMC possibly as part of a negative feed-back mechanism. This up-regulation may cause a local deficiency in vitamin K status leading to the production of inactive, non-carboxylated MGP. Phosphorylated MGP remains attached to the growing calcification crystals while dephosphorylated MGP (dp-MGP) is released into the circulation. Levels of dp-MGP in circulation can be measured and have been found to correlate with cardiovascular morbidity.
Table 1: VKDP used as markers for Vitamin K deficiency and disease states.

<table>
<thead>
<tr>
<th>Organ</th>
<th>Marker protein</th>
<th>Disease</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasculation</td>
<td>MGP</td>
<td>Atheromatous plaque</td>
<td>Shanahan, 1994.31</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diabetes</td>
<td>Thomson, 2010.32</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carotid stenosis</td>
<td>Pop, 2011.33</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coronary Heart Failure (CHF)</td>
<td>Ueland, 2011.27</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Higher mortality in patients with aortic stenosis</td>
<td>Ueland, 2010.25</td>
</tr>
<tr>
<td></td>
<td>Dp-ucMGP</td>
<td>CHF</td>
<td>Ueland, 2011.27</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Higher mortality in hemodialysis patients</td>
<td>Schlieper, 2011.26</td>
</tr>
<tr>
<td></td>
<td>Dp-cMGP</td>
<td>Aortic stenosis and calcification</td>
<td>Cranenburg, 2008.34</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diabetes</td>
<td>Parker, 2010.35</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypertension</td>
<td>Rennenberg, 2010.36</td>
</tr>
<tr>
<td>Bone</td>
<td>Osteoclastin</td>
<td>Glycemic Index</td>
<td>Guntur, 2012.37</td>
</tr>
<tr>
<td></td>
<td>ucOC</td>
<td>Insulin metabolism</td>
<td>Bulló, 2012.38</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bone fractures</td>
<td>Herrmann, 2002.39</td>
</tr>
<tr>
<td>Liver</td>
<td>PIVKA-II</td>
<td>Vitamin K deficiency</td>
<td>Schurgers, 2007.40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Westenfeld, 2012.29</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Holden, 2010.30</td>
</tr>
</tbody>
</table>

Figure 3: The process of vascular calcification. Mineralization of the ECM induces an increase in the expression of MGP as a negative feedback mechanism. The up-regulation of MGP causes a relative deficiency in vitamin K which, if not replenished, will lead to inactive MGP and vascular calcification. A decrease in the expression of calcification inhibitors such as OPN, Osteopontin; PPI, pyrophosphate; BMP-2 and BMP-4, Bone Morphogenetic Protein-2 and 4, respectively, may also result in vascular calcification.

Besides vitamin-K dependent γ-carboxylation, MGP can also be activated through its phosphorylation on 3 serine residues (residues 3, 6 and 9). Once activated, MGP is attracted to hydroxyapatite crystals through the negatively charged phosphate group hence forming a coat on the surface of the crystals. This results in the inhibition of crystal growth by preventing the aggregation of the crystals. Another proposed mechanism of action of MGP is through the binding and inhibition of bone morphogenetic proteins 2 and 4 (BMP-2, BMP-4), members of the transformation growth factor beta (TGF-β) superfamily. BMP-2 promotes the process of calcification by inducing apoptosis, and the trans-differentiation of VSMC into osteoblast-like cells, both of which increase vascular calcification. Additionally, through its binding to vitronectin, a protein that reduces cell apoptosis, MGP influences cell differentiation. Therefore, when MGP is inactive or absent from tissues, the action of BMP becomes pronounced, causing extensive calcification by stimulating VSMC to express osteogenic morphogens. Thereby, VSMC transdifferentiate into osteocyte-like cells and the surrounding ECM becomes mineralized. Indeed, the levels circulating undercarboxylated MGP can be used as an indicator for vascular calcification, whereby an inverse relationship exists between serum ucMGP and the degree of arterial calcification.

Other effects of Vitamin K₂ on vascular calcification

Of the three forms of vitamin K, VK₂ has been shown to exhibit profound effects on reducing vascular calcification. It was found to decrease arterial calcification on cultured bovine aortic smooth muscle cells treated with inorganic phosphate. This effect was amplified when the treatment was combined with bisphosphonates. In another study, VK₂ reduced the advancement of atherosclerosis in hypercholesteremic rabbits. The ability of VK₂ to improve lipid profile by increasing HDL levels and decreasing total cholesterol levels, and therefore affect the process of vascular calcification and plaque formation in atheroma was demonstrated in the Rotterdam study. Dietary VK₂ intake was associated with a lower occurrence...
of aortic calcification and coronary heart disease in those patients. Similarly, a study on post-menopausal women found a lower incidence of coronary calcification with increased consumption of VK$_2$ ormenaquiones, particularly MK-4. In recognition of the effect of VK$_2$ on reducing the risk of coronary heart disease, the International Life Sciences Institute (ILSI Europe), recently recommended taking VK$_2$, in addition to VK$_1$, into consideration when calculating the daily recommended value of vitamin K.

Vascular calcification is associated with a number of diseases. People suffering from familial hypercholesteremia are at high risk of developing aortic calcification. Two other patient populations are especially vulnerable to vascular calcification; patients with renal disease and diabetics. In patients suffering from end-stage renal disease (ESRD), the presence of calcification in their arteries correlates with higher risk of mortality. In this patient population, calcification is probably induced by high calcium and phosphate circulating levels perhaps due to impaired kidney function, or by vitamin K deficiency. A study on hemodialysis patients subjected to varying doses of mk-7 intake resulted in a decrease in serum dp-ucMGP, ucOC and PIVKA-II levels significantly in the group treated with 360 microgram/day, but not at lower doses. In order to sufficiently carboxylate peripheral VKDPs, VK$_2$ is needed at doses near to/or higher than the currently accepted RDA value. The administration of MK-7 reduced ucMGP and dp-ucOC levels significantly at doses near RDA but not significantly at lower doses.

Diabetic patients suffer from calcification in the tunica media mainly in the thoracic aorta, coronary arteries and tibial arteries. The possibility of calcification in these patients is four times higher than in non-diabetics. The incidence of advanced glycation end-products (AGE), which correlates with the occurrence of coronary artery calcification (CAC), may be induced by the elevated blood glucose levels. Alternatively, calcification in these patients may be triggered by vascular inflammation or the formation of foam cells from macrophages that in turn contribute to the calcification process. MGP levels were found to be higher in diabetic patients, with higher ucMGP levels indicating higher risks of mitral arterial calcification a trend that was contrary to that observed in non-diabetics. This indicates that vitamin K dependent proteins may play a role in the observed incidence of calcification in diabetics, an effect which may be counteracted with sufficient vitamin K treatment. While VK$_2$ is being studied for its role in the modulation of calcification, VK$_1$ does not seem to have a significant effect on vascular calcification, as shown in several studies. This may be partially attributed to the VK$_2$ being present in higher concentrations than VK$_1$ in LDL molecules, which target extra-hepatic organs, and is thereby more potent in carboxylating peripheral VKDPs. This may explain the observed anti-calcification effects of VK$_2$ as opposed to VK$_1$. VK$_2$ has been shown to reduce coronary calcification at high intake levels probably through the conversion of VK$_1$ into VK$_2$ in the human body. Besides carboxylating VKDPs, VK$_2$ may exhibit its effect by regulating gene transcription of several proteins involved in calcification. It was found to reduce the levels of osteopontin (OPN) mRNA, while increasing the expression of MGP. These trends were opposite to the ones observed when treatment with inorganic phosphate, a calcification inducer, was used.

Vitamin K antagonists (VKA), such as warfarin and their derivatives, are administered as anticoagulants to many patients. They inhibit the recycling of vitamin K in the epoxide cycle thereby reducing its availability to carboxylate coagulation factors in the liver; however, they have a similar effect on non-hepatic vitamin-K dependent proteins. VKAs were found to cause calcification in human femoral arteries, mitral valves, aortic valves, and rat carotid artery and aorta. Coronary calcification was also observed in arterial fibrillation patients with low-cardiovascular risk, as a cause of VKA treatment. The administration of VKA was associated with higher MGP levels in the vasculature of rats, particularly in the calcified regions. However, a 3 fold decrease in circulating serum MGP was recorded in the treated rats, perhaps due to more MGP becoming attached to the growing crystals. In human subjects, a study by Rennenberg and colleagues suggested higher levels of dephosphorylated, non-carboxylated MGP (dp-ucMGP) in patients using Coumadin for over ten years. Elevated dp-ucMGP levels may indicate peripheral vitamin K deficiency and may serve as a biomarker for vascular calcification. In support of this, normal subjects treated with VKA had elevated dp-ucMGP while those on vitamin K supplementation had decreased levels.

### Figure 4: The effect of vitamin K on MGP and vascular calcification.

Different species of MGP are affected by the presence of vitamin K. These include Dp-cMGP, non-phosphorylated carboxylated MGP; p-cMGP, phosphorylated MGP; p-ucMGP, phosphorylated-non-carboxylated MGP; dp-ucMGP, non-phosphorylated non-carboxylated MGP.

Some concerns regarding the use of VK$_2$ in treatment have been raised, including the possibility of achieving a hypercoagulable state. In fact, a study on hypercholesterolemic rabbits showed that such a state was not reached even when high doses were administered for ten weeks. In human subjects not receiving oral anti-coagulation treatment, no effects of the use of such doses on coagulation was found using a highly sensitive chloramphenicol acetyltransferase.
Nevertheless, the administration of VK₂, especially the longer chain mk-7, should be closely monitored in patients receiving VKA treatment since mk-7 is a 3-4 times more potent inhibitor of VKA than VK₁.⁴⁰,⁸⁰

Conclusion

Vitamin K₂ has promising potential to be used as treatment or prevention for the development of vascular calcification especially in at-risk patient groups with high incidence of calcification or vitamin K deficiency. Through its peripheral distribution in low density lipoproteins, VK₂ exercises its effect by activating various VKDPs including the soft-tissue calcification inhibitor MGP. Clinical trials looking into the effect of VK₂ on vascular calcification and its beneficial cardiovascular effects will help elucidate its potential role as a therapeutic strategy.

Acknowledgements

The authors certify that there is no conflict of interest and no funding was received for this work.

References


